| NCT Number | Conditions | Interventions | Sponsor/Collaborators | Phases | Start Date | Last Updated |
| NCT02047006 | Chronic Renal Failure | Drug: Rivaroxaban 10 mg | AZ Sint-Jan AV|Onze Lieve Vrouw Hospital | Phase 4 | 2013-09-01 | 2015-01-13 |
| NCT02486445 | Deep Venous Thrombosis | Drug: Rivaroxaban | Ostfold Hospital Trust | Phase 3 | 2015-02-01 | 2016-10-10 |
| NCT02970773 | Spinal Cord Injuries|Thromboembolism | Drug: Rivaroxaban | Swiss Paraplegic Centre Nottwil | | 2017-01-01 | 2016-11-18 |
| NCT01598168 | Heparin-induced Thrombocytopenia | Drug: Rivaroxaban | McMaster University | Phase 3 | 2013-01-01 | 2016-03-24 |
| NCT02583191 | Venous Thromboembolism|Cancer | Drug: Rivaroxaban|Drug: low-molecular heparine | AIO-Studien-gGmbH|Charite University, Berlin, Germany|Bayer | Phase 3 | 2016-03-01 | 2016-03-18 |
| NCT01989845 | Rivaroxaban|Cancer-associated Thrombosis|Recurrence|Bleeding | Drug: Rivaroxaban | Seoul National University Hospital|Korean Society of Hematology Thrombosis Working Party | Phase 4 | 2013-10-01 | 2017-01-06 |
| NCT02438098 | Prophylaxis of Venous Thromboembolism | Drug: Rivaroxaban 10 mg | University Hospital Inselspital, Berne|Centre Hospitalier Universitaire Vaudois|Bayer | Phase 1 | 2015-06-01 | 2016-01-07 |
| NCT02657512 | Healthy | Drug: rivaroxaban|Drug: rivaroxaban and activated charcoal | Centre Hospitalier Universitaire de Saint Etienne | Phase 1 | 2016-01-01 | 2016-05-24 |
| NCT02116036 | Antiphospholipid Antibody Syndrome | Drug: Rivaroxaban | St. Joseph's Healthcare Hamilton|Heart and Stroke Foundation of Canada|Bayer|Hamilton Health Sciences Corporation|Jewish General Hospital|University of Alberta|The Ottawa Hospital|Queen Elizabeth II Health Sciences Centre | Phase 4 | 2014-09-01 | 2015-07-23 |
| NCT02072668 | Sickle Cell Anemia|Sickle Cell-Beta0-Thalassemia | Drug: rivaroxaban|Drug: placebo | University of North Carolina, Chapel Hill|National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | 2014-02-01 | 2016-11-02 |
| NCT02157272 | Antiphospholipid Syndrome | Drug: Experimental: Rivaroxaban | University of Padova | Phase 3 | 2014-12-01 | 2015-11-30 |
| NCT02066662 | Atrial Fibrillation or Pulmonary Embolism|Need of Long Term Oral Anticoagulation Therapy (OAT)|Existent Coronary or Valvular Calcification, or Both and Agatston Score > 50 in at Least One Location | Drug: Rivaroxaban or Marcumar | RWTH Aachen University|Bayer | Phase 4 | 2013-07-01 | 2015-12-03 |
| NCT02289703 | End-Stage Renal Disease | Drug: Rivaroxaban 15 mg | Janssen Research & Development, LLC|Bayer | Phase 1 | 2015-01-01 | 2017-01-23 |
| NCT02333929 | Patients Receiving Rivaroxaban Treatment | Device: STA- Rivaroxaban Calibrator&Control | Diagnostica Stago | | 2015-03-01 | 2017-02-13 |
| NCT01708850 | Neoplasm|Central Venous Catheter Thrombosis | Drug: Rivaroxaban | London Health Sciences Centre | Phase 4 | 2012-11-01 | 2016-09-06 |
| NCT02042534 | Ischemic Stroke|Transient Ischemic Attack | Drug: Rivaroxaban|Drug: Warfarin | Asan Medical Center|Bayer | Phase 2 | 2014-01-01 | 2016-12-14 |
| NCT01747746 | Atrial Fibrillation|Stroke|Thrombo-embolism|Bleeding | Drug: Rivaroxaban|Drug: Warfarin and Enoxaparin | John H. Stroger Hospital|Cook County Hospital | Phase 4 | 2012-10-01 | 2015-02-02 |
| NCT02058199 | Gastric Bypass Status | Drug: rivaroxaban | State University of New York - Upstate Medical University | Phase 1 | 2014-12-01 | 2016-01-04 |
| NCT02468102 | Acute Coronary Syndrome | Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Standard of care drugs | Bayer|Janssen Scientific Affairs, LLC | | 2015-06-01 | 2017-03-13 |
| NCT02926170 | Antiphospholipid Syndrome | Drug: Rivaroxaban|Drug: acenocumarol | Hospital Universitari Vall d'Hebron Research Institute | Phase 3 | 2013-03-01 | 2016-10-05 |
